NO20052999L - Ny synergistisk kombinasjon omfattende roflumilast og formoterol - Google Patents

Ny synergistisk kombinasjon omfattende roflumilast og formoterol

Info

Publication number
NO20052999L
NO20052999L NO20052999A NO20052999A NO20052999L NO 20052999 L NO20052999 L NO 20052999L NO 20052999 A NO20052999 A NO 20052999A NO 20052999 A NO20052999 A NO 20052999A NO 20052999 L NO20052999 L NO 20052999L
Authority
NO
Norway
Prior art keywords
formoterol
combination including
synergistic combination
new synergistic
roflumilast
Prior art date
Application number
NO20052999A
Other languages
English (en)
Other versions
NO334247B1 (no
Inventor
Norbert Kolassa
Rolf Beume
Degenhard Marx
Daniela Bundschuh
Christian Weimar
Original Assignee
Takeda Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Gmbh filed Critical Takeda Gmbh
Publication of NO20052999L publication Critical patent/NO20052999L/no
Publication of NO334247B1 publication Critical patent/NO334247B1/no

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)

Abstract

Oppfinnelsen vedrører den kombinerte administtasjon av roflumilast og formoterol for behandlingen av lidelser i det respiratoriske system.
NO20052999A 2002-11-27 2005-06-17 Medikament omfattende roflumilast i kombinasjon med formoterol NO334247B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP02026505 2002-11-27
PCT/EP2003/013275 WO2004047829A1 (en) 2002-11-27 2003-11-26 New synergistic combination comprising roflumilast and formoterol

Publications (2)

Publication Number Publication Date
NO20052999L true NO20052999L (no) 2005-06-17
NO334247B1 NO334247B1 (no) 2014-01-20

Family

ID=32338002

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20052999A NO334247B1 (no) 2002-11-27 2005-06-17 Medikament omfattende roflumilast i kombinasjon med formoterol

Country Status (31)

Country Link
US (1) US20060142308A1 (no)
EP (1) EP1567139B1 (no)
JP (1) JP2006508994A (no)
KR (1) KR101071798B1 (no)
CN (1) CN100346777C (no)
AT (1) ATE399543T1 (no)
AU (1) AU2003292120B2 (no)
BR (1) BR0316451A (no)
CA (1) CA2506962C (no)
CO (1) CO5690570A2 (no)
CY (1) CY1110369T1 (no)
DE (1) DE60321953D1 (no)
DK (1) DK1567139T3 (no)
EA (1) EA009935B1 (no)
ES (1) ES2309357T3 (no)
HR (1) HRP20050579B1 (no)
IL (1) IL168308A (no)
IS (1) IS2575B (no)
MA (1) MA27539A1 (no)
ME (1) ME00489B (no)
MX (1) MXPA05005437A (no)
NO (1) NO334247B1 (no)
NZ (1) NZ540659A (no)
PL (1) PL216752B1 (no)
PT (1) PT1567139E (no)
RS (1) RS51081B (no)
SI (1) SI1567139T1 (no)
TN (1) TNSN05131A1 (no)
UA (1) UA83018C2 (no)
WO (1) WO2004047829A1 (no)
ZA (1) ZA200503308B (no)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY140561A (en) 2002-02-20 2009-12-31 Nycomed Gmbh Dosage form containing pde 4 inhibitor as active ingredient
AU2004220357B2 (en) 2003-03-10 2010-09-30 Astrazeneca Ab Novel process for the preparation of roflumilast
ES2421916T3 (es) * 2005-03-16 2013-09-06 Nycomed Gmbh Forma farmacéutica de sabor enmascarado que contiene roflumilast
DE102005030733A1 (de) * 2005-07-01 2007-01-04 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Arzneimittelkombinationen zur Behandlung von Atemwegserkrankungen enthaltend langwirksame Beta-2-Agonisten und wenigstens einen weiteren Wirkstoff
PT2363130E (pt) * 2006-07-05 2014-06-25 Takeda Gmbh Combinação de atorvastatina ou sinvastatina, inibidores de hmg-coa redutase, com um inibidor da fosfodiesterase 4, tal como roflumilaste, para o tratamento de doenças pulmonares inflamatórias
WO2013077830A1 (en) * 2011-11-25 2013-05-30 Mahmut Bilgic Synergistilly active combinations of roflumilast and carmoterol
US20130172303A1 (en) * 2012-01-03 2013-07-04 Forest Laboratories Holdings Ltd. Roflumilast compositions for the treatment of copd
DK2948148T3 (da) * 2013-01-28 2020-10-26 Incozen Therapeutics Pvt Ltd Metoder til behandling af autoimmune, åndedræts- og betændelsesforstyrrelser ved inhalation af roflumilast n-oxid
CN104800214A (zh) * 2014-01-27 2015-07-29 成都英诺新科技有限公司 一种罗氟司特吸入气雾剂复方及制备方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5795564A (en) * 1991-04-05 1998-08-18 Sepracor, Inc. Methods and compositions for treating pulmonary disorders using optically pure (R,R)-formoterol
KR100331255B1 (ko) * 1993-07-02 2002-10-25 빅굴덴 롬베르그 케미쉐 화부리크 게엠베하 플루오로알콕시-치환된벤즈아미드및시클릭뉴클레오티드포스포디에스테라아제억제제로서의그의용도
IL130658A (en) * 1997-02-17 2004-07-25 Altana Pharma Ag Preparations for the treatment of ARDS or IRDS containing 3 - (cyclopropylmethoxy) - N - (3, 5 - dichloro - 4 - pyridinyl) - 4 - (difluoromethoxy) benzamide and solvent for the lungs
US6624181B1 (en) * 1997-02-28 2003-09-23 Altana Pharma Ag Synergistic combination
PT975347E (pt) * 1997-02-28 2008-05-23 Nycomed Gmbh Combinação sinérgica de inibidores da pde e agonistas da adenilato ciclase ou agonistas da guanil ciclise
BR9913152A (pt) * 1998-08-26 2001-05-15 Smithkline Beecham Corp Terapias para tratamento de doenças pulmonares
US6303145B2 (en) * 1999-05-10 2001-10-16 Sepracor Inc. (S,R) formoterol methods and compositions
SK287231B6 (sk) * 1999-08-21 2010-04-07 Nycomed Gmbh Liečivo zahŕňajúce PDE inhibítor a agonistu beta2 adrenoreceptora
GB0103630D0 (en) * 2001-02-14 2001-03-28 Glaxo Group Ltd Chemical compounds
ATE381537T1 (de) * 2001-03-22 2008-01-15 Glaxo Group Ltd Formanilid-derivative als beta2-adrenorezeptor- agonisten
BR0209271A (pt) * 2001-04-30 2004-06-15 Glaxo Group Ltd Composto, uso de um composto composição farmacêutica, formulação em aerossol farmacêutica, método para o tratamento de um paciente humano ou animal com uma condição inflamatória e/ou alérgica, e, processo para a preparação de um composto

Also Published As

Publication number Publication date
TNSN05131A1 (en) 2007-05-14
MXPA05005437A (es) 2005-08-03
ME00489B (me) 2011-10-10
CN1713903A (zh) 2005-12-28
RS51081B (sr) 2010-10-31
CO5690570A2 (es) 2006-10-31
UA83018C2 (uk) 2008-06-10
HRP20050579A2 (hr) 2006-04-30
RS20050382A (sr) 2007-08-03
IS2575B (is) 2010-02-15
WO2004047829A1 (en) 2004-06-10
EA200500774A1 (ru) 2005-12-29
DE60321953D1 (de) 2008-08-14
CN100346777C (zh) 2007-11-07
ZA200503308B (en) 2006-11-29
DK1567139T3 (da) 2008-11-03
KR101071798B1 (ko) 2011-10-11
ES2309357T3 (es) 2008-12-16
NO334247B1 (no) 2014-01-20
CA2506962C (en) 2012-01-03
IL168308A (en) 2010-12-30
EA009935B1 (ru) 2008-04-28
CY1110369T1 (el) 2015-04-29
BR0316451A (pt) 2005-10-11
NZ540659A (en) 2007-05-31
PT1567139E (pt) 2008-10-01
EP1567139A1 (en) 2005-08-31
PL216752B1 (pl) 2014-05-30
JP2006508994A (ja) 2006-03-16
AU2003292120B2 (en) 2010-01-21
MA27539A1 (fr) 2005-09-01
WO2004047829A8 (en) 2005-06-30
KR20050085104A (ko) 2005-08-29
HRP20050579B1 (hr) 2014-01-31
PL377732A1 (pl) 2006-02-06
CA2506962A1 (en) 2004-06-10
IS7898A (is) 2005-06-20
AU2003292120A1 (en) 2004-06-18
ATE399543T1 (de) 2008-07-15
US20060142308A1 (en) 2006-06-29
HK1081861A1 (en) 2006-05-26
SI1567139T1 (sl) 2008-12-31
EP1567139B1 (en) 2008-07-02

Similar Documents

Publication Publication Date Title
DK1587506T3 (da) Administration af capsaicinoider
DE60331236D1 (de) Orale zusammensetzungen zur behandlung von diabetes
ATE320800T1 (de) Synergistische kombination von roflumilast und salmeterol
CY1110369T1 (el) Νεος συνεργιστικος συνδυασμος ο οποιος περιεχει ροφλουμιλαστη και φορμοτερολη
NO20052420L (no) Farmakologisk behandling av sovnapn±.
ATE447403T1 (de) Cannabinoiden zur behandlung von während des schlafens auftretenden atmungsstörungen
NO20064964L (no) Behandling av svekket respiratorisk funksjon
CY1110368T1 (el) Συνεργιστικος συνδυασμος ο οποιος περιλαμβανει ροφλουμιλαστη και (r,r)-φορμοτερολη
NO20045343L (no) Ny kombinasjon for behandling av luftveisforstyrrelser
NO20045344L (no) Kombinasjon for behandling av luftveisforstyrrelser
EA200500538A1 (ru) Фармацевтическое средство для эндоназального применения при лечении болезней и нарушений нервной системы

Legal Events

Date Code Title Description
CREP Change of representative

Representative=s name: PLOUGMANN & VINGTOFT, POSTBOKS 1003 SENTRUM, 0104

CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: TAKEDA GMBH, DE

CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: TAKEDA GMBH, DE

CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: ASTRAZENECA AB, SE

MM1K Lapsed by not paying the annual fees